65,437 trials
Herpes Zoster · Pneumococcal Infections
Primary: Number of Herpes Zoster and Pneumococcal Vaccinations Administered — 4.50; 1; 1.50; 2 vaccine doses — p==0.202
Major Depressive Disorder
Primary: Remission Based on HDRS, Hamilton Depression Rating Scale, 24 Item. — 5 Participants
Dementia, Alzheimer Type
Primary: Change in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog) — 5.8; -7.2; 4.8 units on the ADAS-cog scale
Development
Primary: Most Preferred Level of Salt Taste — 0.44; 0.34; 0.42; 0.43 mol/L — p=0.30
Posttraumatic Stress Disorder
Primary: Clinician-Administered PTSD Scale (CAPS) — -6.50; -18.60 units on a scale
Bradycardia
Primary: Percentage of Leads Free From Complication — 97.3 percentage of leads complication-free
Infections, Meningococcal
Primary: Percentages of Subjects With hSBA Titers ≥LLOQ Against 4 Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y at 24 Months After Last…
Atrial Fibrillation
Primary: Number of Participants With Clinically Significant Atrial Arrhythmias at 6 Weeks — 4; 12 Participants
Trauma
Primary: Functional Outcome (Consisting of Questionnaire Score, Hamlyn Mobility Score (HMS) Gait/Activities of Daily Living Parameters) — 19.7; 58.2 units on a scale
Headache
Primary: Change in Pain Scores Based on Patient Questionnaire — -2.95; -1.79; -4.49; -2.65 units on a scale of 1-10
Critical Illness
Primary: Plasma Zinc Concentration Over Time — 51.2; 36.4; 37.7; 43.4 mcg/dL
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 100.0 percentage of participants
Preventive Health Services · Health Communication
Primary: Acceptance of Health Message — 5.5; 5.4 units on a scale — p=0.18
Nasal Obstruction
Primary: Change From Baseline NOSE Score — 53.3; 48.1; 53.5 units on a scale — p=<0.0001
Recurrent Melanoma · Stage IV Melanoma · Tumors Metastatic to Brain
Primary: Maximum Tolerated Dose (MTD) of Ipilimumab — 3; 10 mg/kg